Ranbaxy Laboratories Limited has launched a high end anti-infective injectable under the brand name Cilanem. The product has been introduced for the first time in India, by Ranbaxy's Pharma division. The anti-infective injectable having excellent gram positive, gram negative and anaerobic coverage, is used for nosocomial and life-threatening infections. The product is a combination of imipenem with cilastatin, and belongs to the new class of antibacterials - the carbapenems, stated a press release.
Cilanem would compete in the high-end injectable antibiotic segment. Presently molecules like pipericillin + tazobactam, meropenem, and 3rd & 4th generation premium cephalosporin injectables are being used in such indications. Potential market size in India for the product is expected to be around Rs. 150 cr (Source: ORG). Internationally, this molecule is a blockbuster with sales of around US$ 585 million.
Commenting on the product launch, Malvinder Mohan Singh, Regional Director, India, Ranbaxy, said, "The introduction of Cilanem will give the brand a first mover advantage in the highly progressive market and further strengthen the Company' s leadership position in the anti-infective segment"
The product will be promoted by the Pharma division primarily through its dedicated field force of 30 Hospital Business Executives (HBEs) that cover about 80 corporate hospitals and teaching institutions. This would help quicker penetration of the product in the institutions. Intensivists, as well as speciality surgeons like oncosurgeons & plastic surgeons will also be among the core prescribers of the product.